CompletedNot Applicable

Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis

United States37 participantsStarted 2018-02-01

Plain-language summary

This study measures circulating, misfolded ATTR oligomers in asymptomatic ATTRm amyloidosis genetic carriers longitudinally over five years.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with known hereditary ATTR amyloidosis genetic mutations as identified by genetic testing. Exclusion Criteria: * Patients with ATTR amyloidosis identified as wild-type.

What they're measuring

Average % change in oligomers in patients with new onset TTR amyloid symptoms

Timeframe: Annually over 5 years

Trial details

NCT IDNCT03431896

SponsorThe Cleveland Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-03-09

View on ClinicalTrials.gov More Amyloidosis trials